Welcome to our dedicated page for Strata Critical Medical SEC filings (Ticker: SRTA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Strata Critical Medical, Inc. (Nasdaq: SRTA) provides access to the company’s regulatory disclosures as it executes its strategy in time-critical logistics and medical services for the U.S. healthcare industry. While no specific filings are listed here, Strata’s public communications reference documents such as its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, which contain detailed financial statements, risk factors and management’s discussion of its organ logistics and medical services platform.
Through SEC filings, readers can review how Strata reports the performance of its air and ground logistics, surgical organ recovery, organ placement and normothermic regional perfusion services, as well as perfusion staffing and equipment solutions offered under the Trinity Medical Solutions and Keystone Perfusion brands. The company also describes non-GAAP metrics like Adjusted EBITDA, Flight Profit, Flight Margin and various free cash flow measures, with reconciliations to GAAP figures typically presented in these filings or related materials.
Regulatory documents also summarize key corporate events that Strata highlights in its news releases, such as the divestiture of its Passenger business, the rebranding from Blade Air Mobility to Strata Critical Medical, the acquisition of Keystone Perfusion and the move to a single operating and reporting segment. Risk factor sections expand on themes the company mentions in press releases, including competition, reliance on transplant centers and organ procurement organizations, operational risks in organ transport and regulatory changes affecting its activities.
On Stock Titan, SEC filings for SRTA are supplemented with AI-powered summaries that explain complex sections in plain language, highlight important changes across reporting periods and help readers quickly identify disclosures related to organ logistics, medical services, acquisitions and non-GAAP performance measures. Real-time updates from EDGAR, combined with these summaries, make it easier to track how Strata’s regulatory reporting reflects its evolving business model in the U.S. healthcare and transplant ecosystem.
Strata Critical Medical, Inc. Chief Accounting Officer Cohen Amir reported an open-market sale of Class A common stock. On June 8, 2026, he sold 4,655 shares at $5.87 per share. After this transaction, he directly holds 146,608 shares of the company’s common stock.
Strata Critical Medical, Inc. director and Co-CEO Melissa M. Tomkiel reported an open-market sale of 29,730 shares of Class A common stock at $5.87 per share on June 8, 2026. Following this transaction, she directly holds 1,892,774 shares of the company’s Class A common stock.
Strata Critical Medical, Inc. CEO of Logistics Scott M. Wunsch reported an open-market sale of 5,550 shares of Class A common stock at $5.87 per share. After this sale, he holds 625,574 shares directly and 382,987 shares indirectly through a limited liability company of which he is the sole member.
Strata Critical Medical, Inc. reported results of its annual stockholder meeting held on May 28, 2026. Stockholders elected Class II directors William A. Heyburn and Andrew Lauck to serve until the 2029 annual meeting. Heyburn received 46,050,902 votes for and 505,421 withheld, while Lauck received 39,525,159 for and 7,031,164 withheld, with 12,687,496 broker non-votes for each.
Stockholders also ratified Deloitte & Touche LLP as independent registered public accounting firm for the year ending December 31, 2026, with 58,946,832 votes for, 65,815 against, and 231,172 abstentions. In an advisory vote, stockholders approved executive compensation with 38,497,962 votes for, 8,022,682 against, 35,679 abstentions, and 12,687,496 broker non-votes.
Strata Critical Medical, Inc. Chief Accounting Officer Amir Cohen reported open-market sales of company Class A common stock. On May 22, 2026, he sold 40,575 shares at a weighted average price of $5.91 per share. On May 21, 2026, he sold an additional 10,300 shares at a weighted average price of $5.79 per share. After these transactions, Cohen directly held 151,263 shares of Class A common stock. The filing notes that at least one of the transactions was executed under a pre-arranged Rule 10b5-1 trading plan, indicating the sales were scheduled in advance.
Strata Critical Medical, Inc. Chief Accounting Officer Amir Cohen sold 14,306 shares of Class A common stock on May 11, 2026 in an open-market sale at a weighted average price of $5.79 per share. The transaction was executed under a Rule 10b5-1 trading plan adopted on December 10, 2025. Following this sale, Cohen directly holds 202,138 shares of the company’s Class A common stock.
Morgan Stanley Smith Barney LLC submitted a Form 144 notice relating to proposed sales of Common stock tied to equity awards for the issuer with ticker BLDE. The excerpt lists 23,899 Restricted Stock Units dated 09/08/2024 and 41,282 Performance Stock Units dated 03/08/2025. The filing references 05/11/2026 and NASDAQ in the header.
Velibor Krstic filed Amendment No. 3 to a Schedule 13D regarding Strata Critical Medical, Inc., reporting that 1,577,500 warrants to purchase Class A common stock (SRTAW) expired worthless on May 7, 2026.
Following this expiration, Krstic now beneficially owns 0 warrants, representing 0.0% of the warrant class, and therefore ceased to be a beneficial owner of more than five percent of these securities. The warrants had originally been purchased with personal funds, and no cash or other consideration was involved in their expiration.
Strata Critical Medical, Inc. reported that Velibor Krstic, a ten percent owner, had 1,577,500 warrants to purchase Class A Common Stock expire. These warrants, exercisable at $11.50 per share, expired worthless on May 7, 2026 under a Warrant Agreement dated September 12, 2019. Following the expiration, no warrants of this series remain held by the reporting person.
Strata Critical Medical, Inc. notified the Nasdaq Stock Market LLC of the removal of its warrants expiring 05/07/2026 from listing and/or registration under Section 12(b) of the Exchange Act. The notice cites compliance with Rule 17 CFR 240.12d2-2 and indicates the exchange and issuer followed the voluntary withdrawal procedures.